CATL’s IPO pops in Hong Kong
European and Asian investors have pumped record sums into global equity funds that exclude the US market, and shares in Chinese battery maker CATL surged 16 per cent on their debut in Hong Kong. The EU plans to levy a flat fee on billions of small packages entering the bloc, mainly from China. Plus, Israeli Prime Minister Benjamin Netanyahu is facing calls to scale back his military operation in Gaza and let more aid into the enclave.
Mentioned in this podcast:
Investors flock to equity funds that exclude US after Trump’s return to power
Chinese battery maker CATL surges 16% in biggest listing of 2025
EU to impose €2 tax on low-cost items in blow to Temu and Shein
UK halts trade talks with Israel over Gaza offensive
Israel’s Gaza aid plan could lead to ‘war crime’, UN agency chief says
Benjamin Netanyahu says Israel plans to take over all of Gaza
Today’s FT News Briefing was produced by Sonja Hutson, Kasia Broussalian, Lulu Smyth, and Marc Filippino. Additional help from Sam Giovinco, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT’s acting co-head of audio. The show’s theme song is by Metaphor Music.
Read a transcript of this episode on FT.com
Hosted on Acast. See acast.com/privacy for more information.
- Datum:
- Duur:
Gerelateerde podcastafleveringen
/https%3A//assets.pippa.io/shows/621e1a5bf5df83377cc948b8/1706278122517-493986eb673bb33dd830c424a3f966d7.jpeg)
/https%3A//assets.pippa.io/shows/621e1a5bf5df83377cc948b8/1747427713448-55f9b9b6-5556-44a5-9a9f-878759dce865.jpeg)
Meer afleveringen van FT News Briefing
-
Will Germany ban the far-right AfD?
-
CATL’s IPO pops in Hong Kong
European and Asian investors have pumped record sums into global equity funds that exclude the US market, and shares in Chinese battery maker CATL surged 16 per cent on their debut in Hong Kong. The EU plans to levy a flat fee on... -
A warning shot to the Treasuries market
The US may be stepping back from its role as mediator in the war in Ukraine, and US long-term borrowing costs rose to their highest level since late 2023 on Monday. US drugmaker Regeneron has agreed to buy 23andMe out of bankruptcy, and...